2017 European guideline for the management of pelvic inflammatory disease

Jonathan Ross, Secondo Guaschino, Marco Cusini, Jorgen Jensen

Research output: Contribution to journalArticle


The European guideline for the management of pelvic inflammatory disease includes evidence-based advice on the investigation and treatment of pelvic inflammatory disease (PID). It has been updated to acknowledge the role of Mycoplasma genitalium as an important cause of PID with testing now recommended for women presenting with possible PID and for the male partners of women with confirmed M. genitalium infection. Recent evidence suggests that serious adverse events are uncommon when using moxifloxacin and its use is now recommended as a first-line therapy, especially in those women with M. genitalium PID. The potential utility of MRI scanning of the pelvis in excluding differential diagnoses has been highlighted. The use of doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolide antibiotics, which has been associated with increased resistance in M. genitalium.

Original languageEnglish
Pages (from-to)108-114
Number of pages7
JournalInternational Journal of STD and AIDS
Issue number2
Publication statusPublished - Feb 1 2018



  • antibiotics
  • guideline
  • Pelvic infection
  • pelvic inflammatory disease
  • salpingitis
  • treatment

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this